Pemetrexed induced acute kidney injury in patients with non-small cell lung cancer: reversible and chronic renal damage

详细信息    查看全文

• 作者：Giuseppe Rombol脿 ; Franco Vaira ; Matteo Trezzi ; Nadia Chiappini…
• 关键词：Acute kidney injury ; Bone marrow toxicity ; Not small cell lung cancer ; Pemetrexed
• 刊名：Journal of Nephrology
• 出版年：2015
• 出版时间：April 2015
• 年：2015
• 卷：28
• 期：2
• 页码：187-191
• 全文大小：
• 参考文献：1.Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21(14):2636鈥?644CrossRef PubMed
  2.Santoro A, O鈥橞rien ME, Stahe RA, Nackaerts K, Baas P, Karthaus M, Eberhardt W, Paz-Ares L, Sundstrom L, Liu Y, Ripoche V, Blatter J, Visseren-Gru CM, Manegold C (2008) Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemona谋ve patients with malignant pleural mesothelioma: results of the international expanded access program. J Thorac Oncol 3(7):756鈥?63CrossRef PubMed
  3.Schuette WH, Gr枚schel A, Sebastian M, Andreas S, M眉ller T, Schneller T, Guetz S, Eschbach C, Bohnet S, Leschinger MI, Reck M (2013) A randomized phase II study of pemetrexed in combination with cisplatin or carboplatin as first-line therapy for patients with locally advanced or metastatic non-small-cell lung cancer. Clin Lung Cancer 14(3):215鈥?23CrossRef PubMed
  4.Socinski MA, Stinchcombe TE, Hayes DN (2005) The evolving role of pemetrexed (Alimta) in lung cancer. Semin Oncol 32(2 Suppl 2):16鈥?2 (Review)CrossRef
  5.Ciuleanu T, Brodowicz T, Zielinski C et al (2009) Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 374(9699):1432鈥?440CrossRef PubMed
  6.Gr酶nberg BH, Bremnes RM, Fl酶tten O et al (2009) Phase III study by the Norwegian Lung Cancer Study Group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 27(19):3217鈥?224CrossRef PubMed
  7.Hanna N, Shepherd FA, Fossella FV et al (2004) Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22(9):1589鈥?597CrossRef PubMed
  8. http://鈥媤ww.鈥媎rugs.鈥媍om/鈥媝ro/鈥媋limta.鈥媓tml . Accessed 26 Dec 2012
  9. http://鈥媤ww.鈥媢ptodate.鈥媍om . Accessed 27 Feb 2014
  10.Levin A, Warnock DG, Mehta RL et al (2007) Improving outcomes from acute kidney injury: report of an initiative. Am J Kidney Dis 50:1鈥?CrossRef PubMed
  11.Jassem J, Ramlau R, Santoro A et al (2008) Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. J Clin Oncol 26(10):1698鈥?704CrossRef PubMed
  12. http://鈥媍tep.鈥媍ancer.鈥媑ov/鈥媝rotocolDevelopm鈥媏nt/鈥媏lectronic_鈥媋pplications/鈥媍tc.鈥媓tm . Accessed 27 Feb 2014
  13. http://鈥媤ww.鈥媋ccessdata.鈥媐da.鈥媑ov/鈥媎rugsatfda_鈥媎ocs/鈥媗abel/鈥?004/鈥?21462lbl.鈥媝df . Accessed 27 Feb 2014
  14.Paz-Ares LG, De Marinis F, Dediu M et al (2013) PARAMOUNT: final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Clin Oncol 31:2895鈥?902CrossRef PubMed
  15.Glezerman IG, Pietanza MC, Miller V, Seshan SV (2011) Kidney tubular toxicity of maintenance pemetrexed therapy. Am J Kidney Dis 58(5):817鈥?20CrossRef PubMed
  16.Vootukuru V, Liew YP, Nally JV Jr (2006) Pemetrexed-induced acute renal failure, nephrogenic diabetes insipidus, and renal tubular acidosis in a patient with non-small cell lung cancer. Med Oncol 23:419鈥?22CrossRef PubMed
  17.Michels J, Spano JP, Brocheriou I, Deray G, Khayat D, Izzedine H (2009) Acute tubular necrosis and interstitial nephritis during pemetrexed therapy. Case Rep Oncol 2:53鈥?6CrossRef PubMed Central PubMed
  18.Stavroulopoulos A, Nakopoulou L, Xydakis AM, Aresti V, Nikolakopoulou A, Klouvas G (2010) Interstitial nephritis and nephrogenic diabetes insipidus in a patient treated with pemetrexed. Ren Fail 32:1000鈥?004CrossRef PubMed
  19.Porta JM, Vicente de Vera Florist谩n C, Ingl谩n PB, Jeric贸 JF (2009) Acute renal failure associated with Pemetrexed (Alimta庐). Nefrologia 29:610鈥?11PubMed
  20.Chauvet S, Courbebaisse M, Ronco P, Plaisier E. Pemetrexed-induced acute kidney injury leadind to chronic kidney disease. Clin Nephrol. 2014 (Epub ahead of print)
  21.Perazella MA, Markowitz GS (2008) Bisphosphonate nephrotoxicity. Kidney Int 74:1385鈥?393CrossRef PubMed
  22.Bodmer M, Amico P, Mihatsch MJ et al (2007) Focal segmental glomerulosclerosis associated with long-term treatment with zoledronate in a myeloma patient. Nephrol Dial Transplant 22:2366鈥?370CrossRef PubMed
  23.Barri YM, Munshi NC, Sukumalchantra S et al (2004) Podocyte injury associated glomerulopathies induced by pamidronate. Kidney Int 65:634鈥?41CrossRef PubMed
  24.Markowitz GS, Appel GB, Fine PL et al (2001) Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. J Am Soc Nephrol 12:1164鈥?172PubMed
  25.Desikan R, Veksler Y, Raza S et al (2002) Nephrotic proteinuria associated with high-dose pamidronate in multiple myeloma. Br J Haematol 119:496鈥?99CrossRef PubMed
  26.McKeage MJ (1995) Comparative adverse effect profiles of platinum drugs. Drug Saf. 13:228鈥?44CrossRef PubMed
  27.Hannemann J, Baumann K (1990) Nephrotoxicity of cisplatin, carboplatin and transplatin. Arch Toxicol 64:339鈥?00CrossRef
  
• 作者单位：Giuseppe Rombol脿 (1) (3)
  Franco Vaira (2)
  Matteo Trezzi (1)
  Nadia Chiappini (1)
  Valeria Falqui (1)
  Francesco Londrino (1)
  
  1. Nephrology and Dialysis Unit, St. Andrea Hospital, La Spezia, Italy
  3. Nephrology Dialysis and Kidney Transplant, Macchi Foundation Hospital, Via L. Borri 51, Varese, Italy
  2. Oncology Unit, St. Andrea Hospital, La Spezia, Italy
  
• 刊物类别：Nephrology; Urology;
• 刊物主题：Nephrology; Urology;
• 出版者：Springer International Publishing
• ISSN：1724-6059

文摘

Background Pemetrexed (Alimta庐) (PEM) is an antifolate antineoplastic agent effective in several tumor types, such as non-small-cell lung cancer (NSCLC) and mesothelioma, among others. It is almost exclusively excreted by the kidney and an eGFR lower 45 mL/min is a contraindication for its use: above this level PEM administration is considered safe and dose adjustment is not required. Although there are some reported cases of PEM-induced renal injury, its incidence and the negative effects on patients鈥?outcome has not been systematically evaluated.